Summary

KEY FINDINGS
The Asia-Pacific dry eye disease market is set to register a CAGR of 5.60% during the forecast period, 2023-2032. The key growth drivers include the increasing number of ophthalmologists in countries such as India, China, and Japan, in addition to the rising ophthalmic education programs and initiatives for improved eye health.
MARKET INSIGHTS
Australia & New Zealand, India, Japan, Indonesia, China, South Korea, Thailand, and Rest of Asia-Pacific are evaluated for the Asia-Pacific dry eye disease market growth assessment. Dry eye disease (DED) is the most common ocular disease observed in South Korea. As per the research article published in 2019 in the Korean Journal of Family Medicine, female sex, suicidal ideation, a history of cataracts, and hypercholesterolemia are likely to be the risk factors for dry eye symptoms among elderly Koreans. Besides, the country records a rapidly increasing aging population, as well.
On the other hand, as per the survey conducted by Johnson & Johnson Vision in 2019, the majority of people in Thailand, accounting for 77%, frequently suffer from symptoms of Meibomian Gland Dysfunction (MGD) a major cause for dry eye disease. However, while 79% of Thais are not familiar with MGD, 69% choose not to seek medical and professional help, thus, risking their eyesight. Hence, these factors are expected to fuel the dry eye disease market growth in the Asia-Pacific over the forecasting years.
COMPETITIVE INSIGHTS
Key companies operating in the market are Otsuka Holdings Co Ltd, Santen Pharmaceutical Co Ltd, Novartis AG, Sun Pharmaceutical Industries Ltd, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.5. MAJOR MARKET FINDINGS
2.5.1. AIR POLLUTION IS A MAJOR CAUSE OF EYE DISEASES
2.5.2. COVID-19 CONTRIBUTED TO A HIGH NUMBER OF DRY EYE DISEASE CASES
2.5.3. ASIAN RACE IS AT HIGHER RISK OF DEVELOPING DRY EYE DISEASE
2.5.4. EXCESSIVE SCREEN TIME CAN INDUCE DRY EYE SYMPTOMS
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. INTRODUCTION OF NOVEL DIAGNOSTIC TECHNIQUES FOR DRY EYE DISEASE
3.1.2. LAUNCH OF PROMISING PIPELINE PRODUCTS FOR DRY EYE DISEASE
3.1.3. GROWING INCIDENCE AND PREVALENCE OF DRY EYE AMONG DIFFERENT AGE GROUPS
3.2. KEY RESTRAINTS
3.2.1. RISK OF SIDE EFFECTS
3.2.2. SUBSTITUTE THERAPIES
3.2.3. EXPENSIVE SPECIALTY PRODUCTS AND COMPLEX REIMBURSEMENT SCENARIO
4. KEY ANALYTICS
4.1. PARENT MARKET ANALYSIS
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. VALUE CHAIN ANALYSIS
4.7.1. RESEARCH AND DEVELOPMENT
4.7.2. MANUFACTURING
4.7.3. DISTRIBUTORS
4.7.4. POST-SALES MONITORING
5. MARKET BY TYPE
5.1. OTC
5.2. PRESCRIPTION
6. MARKET BY PRODUCT
6.1. ANTI-INFLAMMATORY DRUGS
6.1.1. CYCLOSPORINE
6.1.2. CORTICOSTEROID
6.1.3. OTHER ANTI-INFLAMMATORY DRUGS
6.2. ARTIFICIAL TEARS
6.3. PUNCTAL PLUGS
6.4. SECRETAGOGUES
6.5. OTHER PRODUCTS
7. MARKET BY DISTRIBUTION CHANNEL
7.1. HOSPITAL PHARMACIES
7.2. INDEPENDENT PHARMACIES AND DRUGSTORES
7.3. ONLINE PHARMACIES
8. GEOGRAPHICAL ANALYSIS
8.1. ASIA-PACIFIC
8.1.1. MARKET SIZE & ESTIMATES
8.1.2. ASIA-PACIFIC DRY EYE DISEASE MARKET DRIVERS
8.1.3. ASIA-PACIFIC DRY EYE DISEASE MARKET CHALLENGES
8.1.4. ASIA-PACIFIC DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
8.1.5. KEY PLAYERS IN ASIA-PACIFIC DRY EYE DISEASE MARKET
8.1.6. COUNTRY ANALYSIS
8.1.6.1. CHINA
8.1.6.1.1. CHINA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.1.6.2. JAPAN
8.1.6.2.1. JAPAN DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.1.6.3. INDIA
8.1.6.3.1. INDIA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.1.6.4. SOUTH KOREA
8.1.6.4.1. SOUTH KOREA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.1.6.5. INDONESIA
8.1.6.5.1. INDONESIA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.1.6.6. THAILAND
8.1.6.6.1. THAILAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.1.6.7. AUSTRALIA & NEW ZEALAND
8.1.6.7.1. AUSTRALIA & NEW ZEALAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.1.6.8. REST OF ASIA-PACIFIC
8.1.6.8.1. REST OF ASIA-PACIFIC DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9. COMPETITIVE LANDSCAPE
9.1. KEY STRATEGIC DEVELOPMENTS
9.1.1. MERGERS & ACQUISITIONS
9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
9.1.3. PARTNERSHIPS & AGREEMENTS
9.1.4. BUSINESS EXPANSIONS & DIVESTITURES
9.2. COMPANY PROFILES
9.2.1. AFT PHARMACEUTICALS
9.2.2. ALCON
9.2.3. ALLERGAN PLC (ACQUIRED BY ABBVIE)
9.2.4. BAUSCH HEALTH COMPANIES INC
9.2.5. JOHNSON & JOHNSON
9.2.6. LUMENIS
9.2.7. NOVALIQ GMBH
9.2.8. NOVARTIS AG
9.2.9. OASIS MEDICAL
9.2.10. OTSUKA PHARMACEUTICAL CO LTD
9.2.11. SANTEN PHARMACEUTICAL CO LTD
9.2.12. SENTISS PHARMA PRIVATE LIMITED
9.2.13. SUN PHARMACEUTICAL INDUSTRIES LTD
9.2.14. TEVA PHARMACEUTICAL INDUSTRIES LTD
9.2.15. VISUFARMA